The clinical problem

Excess weight and metabolic dysfunction are not cosmetic concerns. They sit upstream of cardiovascular disease, diabetes, joint disease, and more. For many people, years of effort have not produced durable change — not from lack of discipline, but because the underlying metabolic biology was working against them.

The UroLongevity approach

The GLP-1 receptor agonist class — semaglutide, tirzepatide, and the next-generation compounds — has genuinely changed metabolic medicine. But a prescription is not a plan. Here these tools are used inside the full framework: a metabolic baseline first, then individualized treatment, then monitoring of how your body actually responds, with the lifestyle foundation built in parallel rather than skipped.

◆ Dr. Shusterman’s take

The GLP-1 drugs are the most significant metabolic tool of my career. They are also the most over-simplified. Used without a baseline, without lean-mass tracking, and without a lifestyle foundation, a remarkable tool gets reduced to a number on a scale.

What’s involved

At a high level, evaluation and intervention may include:

  • Metabolic baseline — glucose regulation, insulin dynamics, lipids, inflammatory markers
  • Body composition tracking — so that what is lost is fat, while lean mass is protected
  • GLP-1 class therapy where appropriate — selected and dosed individually
  • Lifestyle foundation — nutrition and resistance training as non-negotiable partners to any medication
  • Ongoing monitoring — response, tolerability, and adjustment over time
On dosing Specific dosing and protocols are individualized to your clinical picture and decided in consultation. They are not published here, because one-size guidance is not good medicine.

Honest expectations

For appropriate patients these medications can be highly effective. They are also not magic, not free of side effects, and not a permanent substitute for the metabolic foundation. The honest framing: they are a powerful tool used inside a plan — not the plan itself.